Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alireza Atri

Showing results (141-150 of 143) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 143 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 14, 2026
Alzheimer's disease polygenic risk in early- and late-onset Alzheimer's diseaseJulian V Pentchev, Trever Jackson, Naazneen Khan, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 15

Showing results (141-150 of 143) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 143 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 14, 2026
Alzheimer's disease polygenic risk in early- and late-onset Alzheimer's diseaseJulian V Pentchev, Trever Jackson, Naazneen Khan, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 15